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Introduction: ALK gene rearrangements occur in approximately 5% 
of lung adenocarcinomas (ACAs), leading to anaplastic lymphoma 
kinase (ALK) overexpression and predicting response to targeted 
therapy. Fluorescence in situ hybridization (FISH) is the standard pro-
cedure for detection of ALK rearrangements in lung ACA but requires 
specialized equipment and expertise. Immunohistochemistry (IHC) 
for ALK protein overexpression is a promising screening modality, 
with reports of newer antibodies showing excellent sensitivity and 
specificity for ALK-rearranged lung ACA.
Methods: In this study, we analyzed ALK IHC (5A4 clone) in 186 
cases from our clinical service and compared it with ALK FISH and 
EGFR and KRAS mutation status.
Results: Twelve cases had concordant ALK protein overexpres-
sion and ALK rearrangement by FISH. Three ALK-rearranged cases 
lacked ALK protein expression. Of these discrepant cases, one had 
a coexisting EGFR mutation and a subtle atypical ALK rearrange-
ment manifested as a break in the 5′ centromeric portion of the FISH 
probe. One case had a concurrent BRAF mutation. Follow-up testing 
on a metastasis revealed absence of the ALK rearrangement, with 
persistent BRAF mutation. In one ALK-rearranged protein negative 
case, very limited tissue remained for ALK IHC, raising the possibil-
ity of false negativity because of protein expression heterogeneity. 
Importantly, ALK protein expression was detected in one case ini-
tially thought not to have an ALK rearrangement. In this case, FISH 
was falsely negative because of interference by benign reactive 
nuclei. After correcting for these cases, ALK IHC was 93% sensitive 
and 100% specific as compared with FISH.
Conclusions: ALK IHC improves the detection of ALK rearrange-
ments when used together with FISH, and its use in lung ACA 
genetic testing algorithms should be considered.
Key Words: Anaplastic lymphoma kinase, Lung adenocarcinoma, 
Fluorescence in situ hybridization, Immunohistochemistry.
(J Thorac Oncol. 2013;8: 322-328)
Rearrangement of the ALK gene occurs in approximately 5% of lung adenocarcinomas (ACAs) and predicts 
response to the targeted inhibitor crizotinib.1 In most cases, 
ALK fuses with EML4 through a small intrachromosomal 
inversion event; however, other translocation events such 
as TFG-ALK and KIF5B-ALK have also been described.2 
Fluorescence in situ hybridization (FISH)–based analysis 
detecting chromosome 2 inversions and other ALK transloca-
tions represents the current standard for diagnosis of ALK-
rearranged lung ACAs.
The National Comprehensive Cancer Network recom-
mends testing for EGFR mutations (by sequence-level analy-
sis) and ALK rearrangement by FISH on all lung ACAs from 
patients with advanced disease.3 EGFR-activating mutations 
are detected in approximately 20% of lung ACAs and predict 
response to epidermal growth factor receptor (EGFR) tyro-
sine kinase inhibitors.4 As a result of these recommendations, 
pathologists have seen a dramatic increase in requests for 
both EGFR mutation analysis and ALK FISH on lung ACA 
specimens.
With FISH as the mainstay for detection of ALK rear-
rangements, the ALK Break Apart FISH Probe Kit (Abbott 
Molecular, Des Plaines, IL) has become a Food and Drug 
Administration–approved companion diagnostic for targeted 
therapy with the ALK inhibitor crizotinib in lung cancers 
(http://www.accessdata.fda.gov/cdrh_docs/pdf11/p110012a.
pdf). However, FISH can be expensive and time-consuming 
and requires specialized fluorescence microscopy equipment 
and expertise. The ALK FISH assay in particular can be dif-
ficult to interpret because the most common alteration, the 
intrachromosomal inversion, leads to a subtle (>2 probe diam-
eter) separation of the 5′ and 3′ signals.5 In addition, cells 
without a rearrangement can, not uncommonly, have some 
nonspecific signal separation. As a result, the assay is prone 
both to false-negatives and false-positives and has significant 
interobserver variability.6
EML4-ALK fusions drive anaplastic lymphoma kinase 
(ALK) transcriptional up-regulation and protein expression.7 
Immunohistochemistry (IHC) for ALK protein expression 
has been available for many years for use in the diagnosis of 
anaplastic large-cell lymphoma, but the traditional antibodies 
for use in lymphoma are insufficiently sensitive for detection 
at the level at which it is expressed in ALK-rearranged lung 
cancers.8 However, several recent studies have demonstrated 
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that a relatively new ALK clone, 5A4, can accurately identify 
ALK-rearranged lung ACA as compared with FISH. Studies 
published from France and Korea comparing the 5A4 antibody 
with ALK FISH demonstrated a sensitivity and specificity of 
95% to 100%.9,10 In contrast, a series from the United States 
(published in abstract form) suggested that the sensitivity of 
the 5A4 antibody is only 82%.11 According to these studies, 
ALK expression can be variable. Although strong staining 
seems to be 100% specific for the presence of rearrangement 
by FISH, weak-to-intermediate staining has been reported 
in FISH-negative tumors. The basis for the discrepancies 
between ALK FISH and IHC is unclear.
In this study, we compare ALK FISH and IHC in a 
cohort of 186 cases derived from our clinical workflow, which 
includes concurrent mutational analysis of EGFR and KRAS. 
We demonstrate that ALK IHC correlates well with FISH. 
However, several discordant cases were identified, including 
two cases that occurred in patients whose tumors harbored 
concurrent oncogene mutations, both with rearrangements 
detected by FISH and negative ALK IHC. In addition, we 
identified two discrepant cases without known concurrent 
oncogenic mutations: one with strong positive ALK protein 
expression and negative FISH results, and one with absent 
ALK protein expression and positive FISH results. We exam-
ined the basis for these discrepancies and determined that in 
most cases, the discrepancies could be resolved either with 
repeat testing or closer analysis of the FISH results, to exclude 
atypical rearrangements unlikely to have functional conse-
quences. As a result of our findings, we propose a clinical test-
ing algorithm that incorporates both ALK IHC and FISH to 
maximize the sensitivity and specificity of detection of ALK-
rearranged lung ACAs.
MATERIALS AND METHODS
Cases were clinically selected for ALK analysis based 
on tumor type, patient characteristics, and tumor stage, from 
September 2010 to April 2012. Clinical histories were derived 
from clinic charts and the electronic medical records, after 
approval by the Brigham and Women’s Hospital or Dana 
Farber Cancer Institute Institutional Review Boards.
Fluorescence In Situ Hybridization
Four µm-thick formalin-fixed, paraffin-embedded tissue 
sections were used for evaluation of ALK genetic status by 
FISH, with the commercial LSI ALK dual color, break-apart 
rearrangement probe (Abbott Molecular, Abbott Park, IL). 
In brief, tissue sections were mounted on positively charged 
slides and air dried. Targeted tumor areas were circled with a 
diamond pen, after review of the corresponding hematoxylin 
and eosin (H&E) slide by a pathologist. Slides were depar-
affinized, dehydrated, immersed in 0.2N HCl for 20 minutes 
then washed and incubated in pretreatment solution at 80°C 
for 30 minutes. Slides were washed, then incubated in 0.5 mg/
ml Protease solution (Paraffin Pretreatment Kit I, Abbott 
Molecular) at 37°C for 35 minutes, washed again, and dried 
at 40 to 50°C on slide warmer for 2 to 5 minutes. The tissue 
was then fixed in 10% buffered formalin at room temperature 
for 10 minutes, washed in Wash Buffer (Abbott Molecular), 
and dried on the slide warmer as described above. Cellular 
DNA was denatured in 70% formamide in 2× SSC pH 7.0 
at 72°C for 5 minutes, and slides were dehydrated at room 
temperature in 70%, 85%, and 100% ethanol for 1 minute 
each, respectively. ALK probe was denatured at 73°C for 5 
minutes. Hybridization was carried out overnight at 37°C. 
Posthybridization wash was performed in 2× SSC, 0.3%NP-
40, pH 7.0 to 7.5 at 72°C for 2 minutes. Slides were counter-
stained with diamidino-2-phenylindole (DAPI) and stored in 
dark at −20°C, before microscope examination.
Results were analyzed with a fluorescence Zeiss Axiophot 
microscope (Carl Zeiss, Oberkochen, Germany). A minimum 
of 50 nuclei from two separate areas of the tumor were inde-
pendently scored by two technologists. Representative images 
were captured, using Leica Microsystem Imaging (Leica 
Microsystems Inc., Buffalo Grove, IL).
Samples were classified as positive for ALK rearrange-
ment when 15% or more of nuclei showed split signals (i.e., 
red and green signals were separated by ≥2 signal diameters) 
or single red signals (3′ ALK) were observed. H&E and FISH 
slides for all cases were reviewed by a pathologist to confirm 
that scoring was carried out in the tumor cell population.
Immunohistochemistry
IHC for ALK was performed on 4 µm-thick formalin-
fixed, paraffin-embedded tissue sections, using clone 5A4 
(Novocastra, Newcastle, United Kingdom). In brief, slides 
were deparaffinized, then treated with Peroxidase Block 
(DAKO, Carpinteria, CA) for 15 minutes to quench endog-
enous peroxidase activity. Antigen retrieval was carried out 
in citrate buffer (pH 6) in a pressure cooker at 122°C for 30 
to 45 minutes. The sections were then incubated with the pri-
mary mouse monoclonal anti-ALK antibody at a 1:50 dilu-
tion for 40 minutes, washed in 50 mM Tris-HCl (pH 7.4), and 
incubated with horseradish peroxidase–conjugated secondary 
antibodies (Envision Plus detection kit, DAKO). Staining was 
developed through incubation with diaminobenzidine, and 
sections were counterstained.
The stained slides were reviewed by two pathologists 
(LMS and JLH) blinded to the FISH results. Staining was 
graded semiquantitatively, as follows: 0 for absent or barely 
perceptible expression in rare cells, 1 (low) for weak to mod-
erate multifocal expression, and 2 (high) for strong staining in 
most cells. All positive cases demonstrated a granular, cyto-
plasmic expression pattern. Focal, weak rimming of intracel-
lular mucin droplets was considered negative.
Mutation Analysis
For mutation analysis, DNA was extracted from 
dissected formalin-fixed, paraffin-embedded, 5µm-thick tissue 
sections, containing more than 50% tumor cells. The EGFR 
kinase domain (exons 18–21) and KRAS exons 2 and 3 were 
amplified using nested polymerase chain reaction, as previously 
described.12,13 Polymerase chain reaction products underwent 
direct bidirectional sequencing by dye terminator sequencing. 
Sequence analysis was performed by using Mutation Surveyor 
(SoftGenetics, State College, PA) and confirmed by qualified 
molecular pathologists (NIL, LMS).
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RESULTS
ALK Fluorescence In Situ Hybridization 
From September 2010 to April 2012, 830 cases under-
went ALK FISH testing in our laboratory, of which 25 (3%) 
demonstrated an ALK rearrangement. Of these, 186 cases, 
including 15 FISH-positive cases, 161 FISH-negative cases, 
and 10 cases that failed by FISH, were tested by ALK IHC. 
The FISH-positive cases included seven balanced rearrange-
ments, characterized by a split signal, and eight unbalanced 
rearrangements, characterized by a loss of the 5′ probe.
ALK Immunohistochemistry
ALK protein expression was detected in 13 cases. ALK 
IHC was negative in 170 cases. Three cases had insufficient 
tumor tissue remaining for IHC interpretation. ALK protein 
expression in positive cases ranged from weak and multifo-
cal (1+) to strong and diffuse (2+) (Fig. 1A). In three cases, 
we noted significant intratumoral heterogeneity, ranging from 
absent to moderate ALK expression (Fig. 1B).
ALK FISH and IHC Correlation
Twelve IHC-positive cases showed an ALK rearrange-
ment by FISH. The intensity of ALK protein expression did not 
correlate with type of ALK rearrangement (data not shown). 
One IHC-positive case did not show an ALK rearrangement at 
the time of initial clinical review. In three IHC-negative cases, 
an ALK rearrangement was detected by FISH. Of the remain-
ing cases, 160 were negative by both IHC and FISH, includ-
ing six cases that were noted to have ALK rearrangements 
detected below the 15% cutoff for positivity (range, 6%–14% 
abnormal cells). Eight cases that were deemed insufficient 
for FISH for technical reasons (i.e., high background, poor 
hybridization, etc.) were scored negative by IHC. Two cases 
failed both FISH and IHC.
Analysis of Cases with Intratumoral Protein  
Expression Heterogeneity
In the three cases with heterogenous ALK protein 
expression, the percentage of tumor cells with rearrangement 
by FISH ranged from 86% to 94%. Although in most cases 
only selected fields are scored by FISH, two cases with ALK 
IHC heterogeneity contained only a small number of tumor 
cells (1 was a cytology cell block and 1 was a needle core 
biopsy) and were scored in their entirety. This observation 
indicates that the ALK rearrangement is a consistent finding 
in the tumor cell population despite variable levels of intratu-
moral ALK protein expression.
Mutation Analysis
EGFR mutation results were available from the tumors 
of all patients, except one who had insufficient material. Of 
these, 36 cases (19%) were EGFR mutated and 151 were wild 
type. KRAS mutation results were available for 146 patients, of 
which 41 (22%) were KRAS mutated and 127 cases were wild 
type, 19 were not tested, and one was insufficient. One case 
contained both an ALK rearrangement by FISH and an EGFR 
(c.2573T>G [p.Leu858Arg]) mutation. None of the ALK 
IHC–positive cases had a concurrent oncogenic mutation.
Examination of Discrepant Cases
Four cases had discrepant ALK FISH and ALK IHC 
results. The discrepancies are categorized as follows: cases 
with presumed atypical or nonfunctional ALK rearrangements 
(false-positive FISH results); cases with false-negative FISH 
results; and cases with false-negative IHC results.
Cases with False-Positive FISH Results
In two cases, additional clinical history was useful 
in interpreting the discrepant results (Table 1): Case 1 was 
a 61-year-old man with a 45 pack-year smoking history and 
large right hilar mass, mediastinal lymphadenopathy, and bony 
metastases at the time of presentation. Cervical mediastinoscopy 
revealed metastatic poorly differentiated lung ACA to level 4 
lymph nodes. Because the patient had aggressive disease and 
significant symptoms at presentation, palliative chemotherapy 
was initiated before the completion of genomic testing. 
Subsequent FISH on the level 4 lymph node specimen showed a 
rearrangement involving the ALK probe in 32% of tumor cells; 
however, ALK IHC was negative. Mutational analysis on that 
same sample revealed wild-type EGFR and KRAS; however, as 
part of a research protocol at the Dana Farber Cancer Institute, 
the patient’s tumor was tested for BRAF mutations and was 
found to have an exon 15 mutation (c.1799T>A [p.Val600Glu]). 
At the time of progression of disease (approximately 5 months 
after diagnosis), the patient was started on a phase I trial of 
crizotinib (DFCI 06-068). Five days after initiating crizotinib, 
the patient was urgently admitted for bowel perforation 
secondary to visceral metastases. He required an emergency 
resection of a small bowel metastasis; ALK FISH performed 
on this specimen was negative, and ALK IHC was negative. 
A BRAF (Val600Glu) mutation was again detected. He died 1 
month later, while under the care of the hospice.
FIGURE 1.  ALK immunohistochemistry in lung ACA reveals 
variable levels of protein expression in ALK rearranged lung 
tumors. (A), Strong and diffuse reactivity (2+) and (B), het-
erogeneous expression ranging from absent to low (1+) in 
two cases with ALK rearrangement by FISH. ALK, anaplastic 
lymphoma kinase; FISH, fluorescence in situ hybridization; 
ACA, adenocarcinoma
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Case 2 was a 65-year-old nonsmoking woman with 
multiple bilateral pulmonary nodules and right pleural effusion 
at the time of presentation. Diagnostic thoracentesis revealed 
lung ACA. Genotyping of tumor revealed an EGFR exon 21 
(c.2573T>G [p.Leu858Arg]) kinase activating mutation. The 
patient was started on erlotinib, and she had a partial response 
with dramatic clinical benefit. Unfortunately, her disease 
progressed, after 9 months of erlotinib at 100 mg as a single 
agent. Pemetrexed was added to the regimen. During one of the 
therapeutic thoracentesis, ALK FISH analysis revealed ALK 
rearrangement, detected in 32 of the 50 nuclei. The patient 
elected not to enroll in any clinical trials at that time. However, 
after three cycles of Pemetrexed and erlotinib therapy, the 
patient decided to stop all treatment for best supportive care. 
After 8 months of best supportive care, the patient decided 
to be reevaluated for possible additional treatment. Another 
diagnostic thoracentesis was performed. ALK FISH was again 
performed. Careful analysis of the FISH results in the tumor 
recurrence revealed an atypical ALK rearrangement that 
involved an asymmetrically split green signal, with a bright 
single green signal, in addition to a small green signal fused 
to a red signal (Fig. 2). The patient was started on erlotinib 
at 100 mg daily, and crizotinib at 200 mg twice daily, though 
the EGFR-sequencing data was pending, . Unfortunately, the 
patient worsened clinically, despite 2 weeks of combination 
treatment. The patient was taken off all therapy and died 2 
days after, while under the care of the hospice. The EGFR 
sequencing data confirmed the presence of a p.Thr790Met 
acquired resistance mutation.
Case with False-Negative FISH Results
A lung wedge biopsy containing ACA underwent ALK 
FISH testing and was negative for a rearrangement. Mutation 
analysis was also negative. ALK IHC revealed 2+ staining in 
tumor cells; however, the cells were present only as small and 
scattered clusters in a background of inflamed and reactive 
lung tissue. Re-review of the original FISH specimen revealed 
that the counts had been performed in an area with exuber-
ant type II pneumocyte hyperplasia, but without tumor cells. 
TABLE 1.  Cases with False-Positive ALK FISH Results
Case Sample Type Testing Date Clnical ALK FISH Report ALK IHC Other Mutations Therapy Follow-Up
1 Lung biopsy September, 2010 Balanced translocation in 32% 
of tumor cells
Negative BRAF c.1799T>A 
(p.Val600Glu)
Chemotherapy,  
crizotinib
Progression
Small bowel metastasis, 
resection
February, 2011 No rearrangement detected Negative BRAF c.1799T>A 
(p.Val600Glu)
- Death
2 Pleural fluid November, 2010 Balanced translocation in 64% 
of tumor cells
Negative EGFR c.2573T>G 
(p.Leu858Arg)
Erlotinib+ 
pemetrexed
Partial response 
× 9 months
Lung core biopsy February, 2012 Atypical ALK rearrangement 
with split centromeric probe
Negative EGFR c.2573T>G 
(p.Leu858Arg) 
and c.2369C>T 
(p.Thr790Met)
Erlotinib +  
crizotinib
Death
ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
TABLE 2.  Cases with False-Negative ALK FISH or ALK IHC Results
Discrepancy Type Sample Type ALK FISH ALK IHC Other Mutations Follow-Up Reason for Discrepancy
FISH false-negative Lung wedge 
biopsy
No translocation 
detected
Positive (2+) WT Repeat FISH on original 
sample: unbalanced 
translocation in 86% 
of tumor cells
Small area of tumor in 
inflamed/ reactive lung; 
first FISH analysis did not 
include tumor
IHC false-negative Lymph node 
biopsy
Unbalanced 
translocation in 
38% of cells
Negative N/A: Insufficient 
material
None available Extremely limited specimen. 
interpret negative results 
with caution
ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; N/A, not applicable.
FIGURE 2.  Atypical rearrangement by FISH using the LSI 
ALK dual color probes (Abbott Molecular) in a patient with a 
coexisting EGFR L858R mutation. The tumor cells show two 
to three normal fused signals and an asymmetrically split 
green (5′ centromeric) signal with a bright single green signal 
(arrow) in addition to a small green signal fused to a red 
signal (arrowhead). ALK, anaplastic lymphoma kinase; FISH, 
fluorescence in situ hybridization; EGFR, epidermal growth 
receptor factor.
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Repeat FISH analysis revealed an ALK rearrangement in 86% 
of tumor cells (Table 2).
Case with False-Negative IHC Results
A lymph node biopsy containing metastatic ACA per-
formed at a referring hospital was received for mutational 
analysis and ALK FISH. There was insufficient tumor to per-
form mutation analysis; however, ALK FISH was carried out 
and revealed an ALK rearrangement in 38% of cells. ALK IHC 
was negative (score of 0) on this specimen; however, less than 
50 tumor cells remained for examination. Clinical follow-up 
is limited on this case (Table 2).
Sensitivity and Specificity of ALK FISH and IHC
Taking the above observations into account, in the end 
we considered 14 cases to contain true ALK rearrangements, 
of which 13 showed IHC positivity, for a sensitivity of 93%. 
The specificity of ALK protein expression for the presence of 
a rearrangement by FISH was 100% (Table 3). In our experi-
ence, the specificity of FISH in clinical practice was 98.5%, 
because of the detection of nonfunctional or atypical ALK 
rearrangements.
DISCUSSION
In this study, we examined a cohort of 186 lung ACA 
cases taken directly from our clinical ALK FISH workflow and 
retrospectively compared the FISH results with ALK IHC. On 
initial analysis, ALK IHC seemed to have limited sensitivity 
for detection of ALK-rearranged lung cancers. Of the 15 cases 
originally identified as containing an ALK rearrangement, 
only 12 demonstrated clear positive ALK expression (sensitiv-
ity of 80%). However, careful analysis of the clinical, genetic, 
and FISH studies in these discrepant cases indicated that this 
conclusion was unwarranted. In two discrepant cases, simul-
taneous oncogenic mutations were identified, and most litera-
ture supports the observation that at best, ALK rearrangements 
occur rarely with oncogenic mutations.14 In one such case of 
a patient with a concurrent BRAF activating mutation, the 
ALK-rearranged clone was detected only at the time of diag-
nosis and was absent in a distant metastasis. This observation, 
together with the absent ALK protein expression, led to the 
argument that the detected rearrangement was either a techni-
cal artifact, or if truly present, was likely not transcribed or 
translated, and was lost during disease progression.15
In another case of a patient with an ALK rearrangement 
and EGFR-activating mutation, careful analysis of the FISH 
results in the tumor recurrence revealed an atypical rearrange-
ment characterized by an asymmetric splitting of the 5′ probe. 
The significance of this alteration is unclear, although this 
cytogenetic finding has not been associated with ALK activa-
tion. Importantly, such asymmetric split signals could easily 
lead to false-positive interpretation, especially in suboptimal 
specimens with weak green probe signals, as was likely the 
case in the original specimen examined from this patient. It 
will be important to determine whether these atypical rear-
rangements can produce an ALK fusion product that is not 
detectable by IHC (such as through RNA analysis); unfor-
tunately, this type of analysis was not possible in this case 
because of the limited size of the tumor sample. Clinically, 
this patient’s course was consistent with having a driver muta-
tion in the EGFR gene, as she originally responded to EGFR 
tyrosine kinase inhibitor treatment, and at the time of relapse 
was found to have the p.Thr790Met EGFR tyrosine kinase 
inhibitor resistance mutation, described in approximately 50% 
of patients who progress through targeted therapy.16
Importantly, IHC also detected an additional ALK-
rearranged case that would have been missed by relying on 
FISH alone. In this case, a large section of lung tissue, in which 
the tumor was present only as isolated nests in a background 
of reactive pneumocyte hyperplasia, was originally scored as 
FISH-negative for ALK rearrangement. Even on H&E stained 
slides, reactive pneumocyte hyperplasia can sometimes be 
difficult to distinguish from neoplasia. Identification of small 
nests of tumor in a reactive background is significantly more 
difficult with fluorescence microscopy. Prompted by the 
positive ALK IHC, the original slide was reexamined, and an 
ALK rearrangement was identified in the tumor cells.
In the final discrepant case, ALK FISH was positive and 
IHC was negative. However, tumor tissue was extremely lim-
ited in this case, no mutation data was available, and because 
the slide was sent from a referring hospital, the specifics of 
fixation and tissue handling were unclear. In the absence of 
corresponding mutation analysis or additional material on 
which to confirm the results, we cannot entirely exclude the 
possibility that the FISH result represents a false-positive. 
Alternatively, this discrepancy may indeed reflect a falsely 
negative IHC. We have detected ALK protein expression 
heterogeneity in a subset of cases stained; in the absence of 
obvious heterogeneity at the chromosomal level, one may 
conclude that ALK protein expression heterogeneity likely 
reflects intratumoral differences in transcription and protein 
processing. These observations suggest that negative results 
on very limited tumor tissue, as with other immunohistochem-
ical and genetic studies, should be interpreted with caution.
These findings argue for a combined FISH and IHC 
approach to maximize the sensitivity and specificity of detec-
tion of ALK-rearranged lung cancers. Because of its reliance 
on specialized equipment and personnel, the use of FISH in 
TABLE 3.  ALK Immunohistochemistry As Compared with 
ALK FISH Results After Comprehensive Molecular and Clinical 
Review of Discrepant Cases
ALK FISH
A
L
K
 
im
m
un
oh
is
to
ch
em
is
tr
y Positive Negative Total
Negative 1 162 163
Low (1+) 4 0  4
High (2+) 9 0  9
Total positive 13 0  13
Total 14 162 176a
a Total case tally does not include 10 cases that were insufficient either by FISH or 
IHC. ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization.
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any diagnostic algorithm frequently introduces some delay 
and may be uninterpretable in cases with nuclear overlapping, 
crush artifact, or technical limitations. IHC can be readily 
incorporated into the surgical pathology workflow, has less 
than a 1 day turnaround time, and is a robust technique that 
may deliver results even when the FISH fails.
Keeping in mind that an individual institution’s testing 
practice depends on local resources, expertise, and reimburse-
ment, we propose that an algorithmic approach to molecular 
diagnosis in lung carcinoma can help to control costs, elimi-
nate unnecessary testing, and improve turnaround time. In our 
hospital, we have instituted a diagnostic algorithm that com-
bines ALK IHC, EGFR and KRAS mutation analysis, and ALK 
FISH. This algorithm operates under the assumption that these 
alterations essentially occur in a mutually exclusive fashion. 
Although KRAS alterations are not targetable, the presence 
of a KRAS mutation identifies a substantial number of cases 
that do not require ALK FISH analysis. This algorithm uses 
sequential testing as follows: (1) targeted analysis of EGFR 
exons 19 and 21; if negative, move to (2) targeted analysis 
of KRAS codons 12 and 13; and if negative, move to (3) ALK 
FISH and Sanger sequencing of EGFR exons 18 to 21 and 
KRAS exons 2 and 3 (Fig. 3; additional details regarding tar-
geted mutation analysis are available upon request). ALK IHC 
is ordered upfront; if this returns positive, the treating oncolo-
gist will immediately be informed, thereby accelerating the 
initiation of targeted therapy. ALK IHC–positive cases will 
undergo confirmatory ALK FISH analysis using the Food and 
Drug Administration–approved kit. Even as next-generation 
sequencing becomes more pervasive in clinical laboratories, 
ALK IHC can complement molecular analysis to more rapidly 
triage cases for ALK FISH testing.
Although FISH is considered the standard procedure for 
the diagnosis of ALK rearrangement, this review of our clinical 
experience with ALK FISH testing indicates that it is prone 
both to false-negative and false-positive results. In the absence 
of comprehensive outcome data on this population, we cannot 
draw conclusions about the true sensitivity and specificity of 
FISH and IHC in predicting response to crizotinib therapy. 
However, institution of prospective IHC and FISH analysis in 
clinical diagnostics will help address this issue.
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